2026 Neuro-oncology Reading List

Reading List

Please click below to access the 2026 Neuro-oncology reading list.

2026 Neuro-oncology Reading List »

C-cert Activity Description

The Continuous Certification (C-cert) activities provide subspecialty learning and knowledge assessment to ensure that diplomates are staying up to date on the latest science, treatments, and therapeutics relating to their subspecialty. The annual activities include: 1) reading the subspecialty  journal articles, and 2) taking and passing the 25-question online post-reading quiz to assess knowledge gained from the journal article content. 

Learning Objectives

Upon completion of this UCNS C-cert activity, participants will be able to:
  • Understand the use of novel targeted agents for pediatric neuro-oncologic conditions 
  • Apply the results gathered from prospective clinical trials in the management of IDH-mutant glioma
  • Apply guideline recommendations in the management of leptomeningeal disease
  • Apply up-to-date treatment approaches for the management of brain metastases

Core Competencies

This UCNS C-cert activity covers the following core competencies:
  • Medical Knowledge
  • Patient Care
  • Practice-Based Learning and Improvement

Disclosures

The UCNS complies with all standards and policies of the ACCME, including identification and resolution of all conflicts of interest prior to the educational activity being delivered to learners. Accordingly, UCNS  planners, authors, and staff comply with the UCNS’s Conflicts of Interest Policy

2026 C-cert Activity Planner (Certification Council) Disclosures
All relevant financial relationships have been mitigated.

Neuro-oncology Certification Examination Committee Contributors

Christian Grommes, MD, Chair, Memorial Sloan Kettering Cancer Center  
Disclosures: Received compensation for consulting from Ono, Roche, Kyowa Kirin, and Curis. Received compensation from Ono for giving a presentation. 

Andrea Wasilewski, MD, Vice Chair, Givens Brain Tumor Center  
Disclosures: Received consultant compensation from Novocure and Servier.  

David M. Cachia, MD, UMass Memorial Medical Center  
Disclosures: Received consultant compensation from Guidepoint Global LLC, Dedham Group, Gerson Lehrman Group, Aptitude Health, M3 Global, Novocure, and Putnam Associates. Received compensation as paid speaker for Massachusetts Neurological Society.  

Cynthia J. Campen, MD, Stanford Medicine Children’s Health  
Disclosures: Received research support from The Greathouse Family Foundation.  

Ashley P. Ghiaseddin, MD, University of Florida  
Disclosures: Received advisory board/consulting compensation from Novocure, Curio Science, Aptitude Health, Servier, Ono Pharma USA, and Alexion Pharmaceuticals. Received consulting compensation from Neosoma, Monteris Medical, Guidepoint, Vita Access, Putnam Associates, and Sago Health. Received marketing consulting compensation from Quessential. Received research support from Novocure - paid to department for clinical trial. Serve on advisory board for Telix. Owns stock in CRISPR Therapeutics AG. 

Brett J. Theeler, MD, Uniformed Services University, School of Medicine 
Disclosures: Nothing to disclose.  

Jerome J. Graber, MD, MPH, Alvord Brain Tumor Center  
Disclosures: Received consultant compensation from Guidepoint and M3 marketing, Servier Inc, and AccessHope network. Received compensation from American Society of Neuroimaging social media editor; Received compensation from Binaytara Foundation, speaker for oncology review course. Performed non-compensated service on editorial boards of Practical Neurology, Neuro-Oncology: Practice, Journal of Neuroimaging, and Journal of Pain and Symptom Management. Served on American Academy of Neurology eLearning subcomittee, Question of the Day committee, and RITE exam committee. 

Emily Hanzlik, MD, St. Jude Children’s Research Hospital 
Disclosures: Receives royalties yearly for authoring an article on Up-to-Date in 2023 (High-grade gliomas in children and adolescents).  

Maria J. MacDonald, MD, London Health Sciences Ctr, Univ. of Western Ontario  
Disclosures: Nothing to disclose.  

Lauren Schaff, MD, Memorial Sloan Kettering Cancer Center  
Disclosures: Received consultant compensation from Servier - one time consultant Ono - one time consultant. Received advisory board compensation from BTG, plc (SERB) - scientific advisory board. Received research support from BTG, plc, and support from Merck in the form of drug supply only. Received honoraria from AAN for speaking engagement.  

Lauryn Hemminger, MD, University of Rochester Medical Center  
Disclosures: Nothing to disclose.  

Staff Contact

Bryan Hagerla, Continuous Certification Manager
Disclosures: Nothing to disclose.
[email protected]
(612) 928-6326